サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1758045

血漿の世界市場

Blood Plasma

出版日
ページ情報
英文 282 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.63円
血漿の世界市場
出版日: 2025年06月27日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 282 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

血漿の世界市場は2030年までに515億米ドルに達する見込み

2024年に329億米ドルと推定される血漿の世界市場は、2024年から2030年にかけてCAGR 7.8%で成長し、2030年には515億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるヒト血漿ソースは、CAGR 9.2%を記録し、分析期間終了までに357億米ドルに達すると予想されます。合成血漿源セグメントの成長率は、分析期間中CAGR 5.0%と推定されます。

米国市場は90億米ドル、中国はCAGR12.4％で成長予測

米国の血漿市場は2024年に90億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに111億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは12.4%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.8%と7.5%と予測されています。欧州では、ドイツがCAGR 5.2%で成長すると予測されています。

世界の血漿市場- 主要動向と促進要因のまとめ

血漿が現代医療において重要なコンポーネントと考えられている理由とは？

血液の麦わら色の液体部分である血漿は、タンパク質、抗体、凝固因子、電解質を豊富に含むため、現代医療において極めて重要な役割を果たしています。主に外傷時の輸血に使用される全血とは異なり、血漿はその治療特性が評価され、幅広い救命治療に加工されています。その中には、免疫不全のための免疫グロブリン、重症患者の容積拡大のためのアルブミン、血友病やその他の出血性疾患の人のための凝固因子などが含まれます。血漿はまた、他の方法では実行可能な治療選択肢がほとんどないような希少疾患、慢性疾患、遺伝性疾患の治療にも使用されています。慢性疾患の増加、免疫系障害、世界の公衆衛生上の緊急事態を受け、血漿由来の治療法はこれまで以上に重要になってきています。例えば、COVID-19パンデミックの際には、回復した患者からウイルスと闘っている患者へ抗体を移行させる可能性のある回復期血漿が注目され、新たな健康脅威への対応における血漿の適応性と重要性が強調されました。さらに、再生可能な生物学的資源であると同時に生物製剤の基礎成分でもあるという血漿のユニークな性質は、製薬会社やヘルスケアプロバイダーにとって血漿を不可欠なものとしました。血漿に対する世界のニーズは増加の一途をたどっており、収集、処理、公平な流通システムが非常に重要となっています。治療用途が拡大し、需要が高まるにつれて、血漿は、救急医療と長期的な疾病管理の両方において、かけがえのない柱としての地位を確固たるものにしています。

血漿分画と処理の進歩はどのように業界を変革しているのか？

血漿分画（生の血漿からさまざまな治療成分を分離するプロセス）における技術革新は、血漿を用いた治療の効率性、拡張性、安全性を劇的に向上させています。長年にわたり、従来の低温エタノール分画法は、免疫グロブリン、アルブミン、凝固因子を含む様々な血漿タンパク質を正確に抽出できる高度に専門化された多段階プロセスへと進化してきました。クロマトグラフィーやナノろ過などの新しい技術は、ウイルス汚染のリスクを最小限に抑えながら純度レベルをさらに高め、患者の転帰と規制遵守の両方を改善しています。このような進歩により、メーカーは歩留まりを最適化し、生産コストを削減し、納期を短縮することが可能となっています。これは、血漿の世界の不足とその誘導体に対する需要の増加を考えると極めて重要なことです。自動化とデジタル追跡はまた、品質管理、トレーサビリティ、在庫管理を合理化し、バリューチェーン全体をより効率的で透明性の高いものにしています。技術的進歩に加え、バイオ製薬企業と学術研究機関との連携が、より広範な疾患を対象とする次世代血漿由来治療法の開発における技術革新に拍車をかけています。個別化医療もまた、特定の血漿タンパク質を個々の患者のニーズに合わせてどのように調整・強化できるかを研究することで、一因となりつつあります。これらの技術が成熟すれば、自己免疫疾患、神経疾患、希少疾患の治療に新たな可能性が開けると期待されています。処理と生産における進歩は、血漿療法をより利用しやすく、より安全なものにし、世界の血漿産業がより強固で迅速なものとなるための基礎を築きつつあります。

世界な献血慣行と倫理的配慮はサプライチェーンにどのような影響を与えているか？

世界な血漿サプライチェーンはヒトドナーに大きく依存しているため、倫理的な収集方法、ドナー報酬モデル、および献血インフラは、安定した持続可能な血漿供給を確保する上で極めて重要です。現在、米国は世界の血漿収集の大部分を占めており、世界全体の供給量の60％以上を占めています。対照的に、多くの欧州諸国は倫理的な懸念とドナーの安全性を理由に金銭的補償を制限または禁止しており、その結果、収集量は比較的少なくなっています。このため、供給の不均衡が著しく、多くの国が国内の治療ニーズを満たすために輸入血漿に頼っています。このような格差は、ドナー募集のベストプラクティスや、生物学的資源を商品化することの道徳性について、国際的な議論を巻き起こしています。世界保健機関（WHO）や欧州医薬品庁（EMA）などの規制機関は、自発的で無報酬の献血を提唱し続けているが、血漿療法に対する世界の需要の高まりは、こうした原則を圧迫しています。この課題に対処するため、いくつかの国では国内の収集インフラ、意識向上キャンペーン、非営利および民間の収集機関との提携に投資しています。血漿は厳しい温度とタイミングの要件の下で収集、輸送、処理されなければならないため、ロジスティクスとコールドチェーン管理も重要な役割を果たします。一方、ドナーの安全性、透明性、倫理的調達は、政府と消費者の双方にとって依然として最大の関心事です。サプライチェーンの効率性、ドナーの権利、倫理基準のバランスを取ることは、複雑ではあるが、血漿業界の将来の安定にとって極めて重要な要素です。

世界の血漿市場の成長を促進する主な要因は何か？

血漿市場の成長は、人口動向、技術の進歩、ヘルスケア政策の変化、世界の疾病負担の増加など、いくつかの連動した要因によって牽引されています。最も影響力のある要因の一つは、免疫不全症、血友病、遺伝性血管性浮腫など、血漿由来療法に効果的な管理を依存する慢性疾患や希少疾患の罹患率の増加です。高齢者は免疫機能障害、外科手術による回復の必要性、血漿製剤を必要とする重篤な疾患に罹患する可能性が高いためです。さらに、希少疾患に対する認識と診断が高まり、専門医療へのアクセスが改善されたことで、これらの治療を必要とする患者層が拡大しています。技術面では、血漿の収集、処理、保管の改善により、製造業者はより効率的に事業を拡大できるようになり、需要の増加に迅速に対応できるようになっています。国内での血漿採取を奨励する政府の政策や官民パートナーシップも、特に歴史的に輸入に頼ってきた国々では役割を果たしています。さらに、バイオ医薬品企業からの強力な投資と血漿由来治療の臨床研究の急増により、製品パイプラインと治療用途が拡大しています。また、特に新興経済圏では、償還制度の進化、規制当局の承認、世界のヘルスケアインフラの強化も市場の成長を後押ししています。これらの要因が相まって、血漿市場は継続的に拡大するための肥沃な環境が整いつつあり、血漿由来製品が現代的で精度の高い、救命医療の進化において重要な役割を果たしていることが明らかになりつつあります。

セグメント

供給源（ヒト血漿供給源、合成血漿供給源）、用途（治療用途、診断用途、研究開発用途）

調査対象企業の例（注目の48社）

  • ADMA Biologics Inc.
  • Baxter International Inc.
  • Bio Products Laboratory Ltd（BPL）
  • Biotest AG
  • Canadian Blood Services
  • Canadian Plasma Resources
  • Cerus Corporation
  • China Biologic Products Holdings
  • CSL Behring
  • Emergent BioSolutions Inc.
  • Grifols S.A.
  • Green Cross Corporation
  • Hualan Biological Engineering Inc.
  • Intas Pharmaceuticals Ltd.
  • Kamada Ltd.
  • Kedrion Biopharma
  • LFB S.A.
  • Octapharma AG
  • Sanquin Blood Supply Foundation
  • Takeda Pharmaceutical Company Ltd.

AI統合

検証された専門家のコンテンツとAIツールにより、市場情報と競合情報を変革します。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP36400

Global Blood Plasma Market to Reach US$51.5 Billion by 2030

The global market for Blood Plasma estimated at US$32.9 Billion in the year 2024, is expected to reach US$51.5 Billion by 2030, growing at a CAGR of 7.8% over the analysis period 2024-2030. Human Plasma Source, one of the segments analyzed in the report, is expected to record a 9.2% CAGR and reach US$35.7 Billion by the end of the analysis period. Growth in the Synthetic Plasma Source segment is estimated at 5.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$9.0 Billion While China is Forecast to Grow at 12.4% CAGR

The Blood Plasma market in the U.S. is estimated at US$9.0 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$11.1 Billion by the year 2030 trailing a CAGR of 12.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.8% and 7.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.2% CAGR.

Global Blood Plasma Market - Key Trends & Drivers Summarized

Why Is Blood Plasma Considered a Critical Component in Modern Medicine?

Blood plasma, the straw-colored liquid portion of blood, plays a pivotal role in modern medicine due to its rich composition of proteins, antibodies, clotting factors, and electrolytes. Unlike whole blood, which is primarily used for transfusions in trauma cases, plasma is valued for its therapeutic properties and is processed into a wide range of life-saving treatments. These include immunoglobulins for immune deficiencies, albumin for volume expansion in critically ill patients, and clotting factors for individuals with hemophilia and other bleeding disorders. Plasma is also used in treating rare, chronic, and genetic conditions that would otherwise have few viable treatment options. In the wake of rising chronic illnesses, immune system disorders, and global public health emergencies, plasma-derived therapies are becoming more critical than ever. During the COVID-19 pandemic, for example, convalescent plasma drew attention for its potential to transfer antibodies from recovered patients to those battling the virus, highlighting the adaptability and importance of plasma in responding to emerging health threats. Furthermore, the unique nature of plasma-being both a renewable biological resource and a foundational ingredient for biologics-has made it an essential focus for pharmaceutical companies and healthcare providers. The global need for plasma continues to grow, placing immense importance on collection, processing, and equitable distribution systems. As therapeutic applications broaden and demand intensifies, blood plasma is solidifying its status as an irreplaceable pillar of both emergency care and long-term disease management.

How Are Advancements in Plasma Fractionation and Processing Transforming the Industry?

Technological innovations in plasma fractionation-the process by which different therapeutic components are separated from raw plasma-are dramatically enhancing the efficiency, scalability, and safety of plasma-based therapies. Over the years, traditional cold ethanol fractionation methods have evolved into highly specialized, multi-step processes that enable precise extraction of various plasma proteins, including immunoglobulins, albumin, and coagulation factors. Newer techniques such as chromatography and nanofiltration have further increased purity levels while minimizing the risk of viral contamination, improving both patient outcomes and regulatory compliance. These advancements are enabling manufacturers to optimize yield, reduce production costs, and accelerate turnaround times, which is crucial given the global shortage of plasma and increasing demand for its derivatives. Automation and digital tracking are also streamlining quality control, traceability, and inventory management, making the entire value chain more efficient and transparent. In addition to technological progress, collaborations between biopharmaceutical companies and academic research institutions are spurring innovation in developing next-generation plasma-derived therapies that can target a broader range of diseases. Personalized medicine is also becoming a factor, with research into how specific plasma proteins can be tailored or enhanced to suit individual patient needs. As these technologies mature, they are expected to open new possibilities in treating autoimmune disorders, neurological conditions, and rare diseases. Collectively, advancements in processing and production are making plasma therapies more accessible and safer, laying the groundwork for a more robust and responsive global plasma industry.

How Are Global Donation Practices and Ethical Considerations Impacting Supply Chains?

The global blood plasma supply chain is heavily dependent on human donors, making ethical collection practices, donor compensation models, and donation infrastructure pivotal to ensuring a stable and sustainable plasma supply. Currently, the United States dominates global plasma collection, accounting for more than 60% of the total global supply, largely due to its allowance of paid plasma donations-a policy not universally accepted. In contrast, many European countries restrict or prohibit monetary compensation, citing ethical concerns and donor safety, resulting in comparatively lower collection volumes. This has led to a significant supply imbalance, with many countries relying on imported plasma to meet domestic therapeutic needs. These disparities are sparking international debate about best practices for donor recruitment and the morality of commodifying a biological resource. Regulatory bodies such as the World Health Organization (WHO) and the European Medicines Agency (EMA) continue to advocate for voluntary, non-remunerated donations, but the growing global demand for plasma therapies is putting pressure on these principles. To address this challenge, several nations are investing in domestic collection infrastructure, awareness campaigns, and partnerships with nonprofit and private collection agencies. Logistics and cold-chain management also play a vital role, as plasma must be collected, transported, and processed under stringent temperature and timing requirements. Meanwhile, donor safety, transparency, and ethical sourcing remain top concerns for both governments and consumers. Striking a balance between supply chain efficiency, donor rights, and ethical standards is a complex but crucial component of the plasma industry’s future stability.

What Are the Key Factors Driving Growth in the Blood Plasma Market Worldwide?

The growth in the blood plasma market is driven by several interlinked factors spanning demographic trends, technological advancements, healthcare policy changes, and rising global disease burdens. One of the most influential drivers is the growing incidence of chronic and rare diseases that rely on plasma-derived therapies for effective management, including immunodeficiencies, hemophilia, and hereditary angioedema. Aging populations in developed countries are also fueling demand, as older individuals are more likely to suffer from immune dysfunction, surgical recovery needs, and critical illnesses that require plasma products. Additionally, increasing awareness and diagnosis of rare diseases, supported by improved access to specialized healthcare, are expanding the patient pool in need of these therapies. On the technological side, improvements in plasma collection, processing, and storage are enabling manufacturers to scale operations more efficiently, thus meeting growing demand more rapidly. Government policies encouraging domestic plasma collection and public-private partnerships are also playing a role, particularly in countries that historically relied on imports. Furthermore, strong investment from biopharmaceutical companies and a surge in clinical research for plasma-derived treatments are expanding the product pipeline and therapeutic applications. Market growth is also bolstered by evolving reimbursement structures, regulatory approvals, and enhanced global healthcare infrastructure, particularly in emerging economies. Together, these drivers are creating a fertile landscape for continued expansion in the plasma market, underscoring the critical role that plasma-derived products play in the evolving landscape of modern, precision-driven, and life-saving healthcare.

SCOPE OF STUDY:

The report analyzes the Blood Plasma market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Source (Human Plasma Source, Synthetic Plasma Source); Application (Therapeutic Use Application, Diagnostic Use Application, Research & Development Application)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

  • ADMA Biologics Inc.
  • Baxter International Inc.
  • Bio Products Laboratory Ltd (BPL)
  • Biotest AG
  • Canadian Blood Services
  • Canadian Plasma Resources
  • Cerus Corporation
  • China Biologic Products Holdings
  • CSL Behring
  • Emergent BioSolutions Inc.
  • Grifols S.A.
  • Green Cross Corporation
  • Hualan Biological Engineering Inc.
  • Intas Pharmaceuticals Ltd.
  • Kamada Ltd.
  • Kedrion Biopharma
  • LFB S.A.
  • Octapharma AG
  • Sanquin Blood Supply Foundation
  • Takeda Pharmaceutical Company Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Blood Plasma - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Immunoglobulins and Albumin Throws the Spotlight on Blood Plasma as a Critical Biologic Resource
    • Global Expansion of Plasma Collection Infrastructure Spurs Growth in Fractionation and Processing Capacity
    • Here's How Chronic Disease Treatment and Autoimmune Therapies Are Driving Plasma-Derived Product Demand
    • Increased Use in Hemophilia, Primary Immunodeficiency, and Transplant Patients Expands Therapeutic Indications
    • Growing Focus on Self-Sufficiency Drives National Investment in Domestic Plasma Collection Networks
    • Here's the Story: How Plasma Donation Incentives and Donor Engagement Platforms Are Supporting Supply Resilience
    • Advancements in Fractionation Technology Improve Yield Efficiency and Safety of Plasma-Derived Therapies
    • Public Awareness Campaigns and NGO Collaborations Support Voluntary and Paid Donation Models Globally
    • Emerging Research into Hyperimmune Globulins and Plasma-Derived Anti-Virals Unlocks New R&D Opportunities
    • Ethical, Logistical, and Biosecurity Concerns Around Donor Eligibility and Contamination Risk Influence Policy
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Blood Plasma Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Blood Plasma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Blood Plasma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Blood Plasma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Human Plasma Source by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Human Plasma Source by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Human Plasma Source by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Synthetic Plasma Source by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Synthetic Plasma Source by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Synthetic Plasma Source by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Therapeutic Use Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Therapeutic Use Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Therapeutic Use Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Diagnostic Use Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Diagnostic Use Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Diagnostic Use Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Research & Development Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Research & Development Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Research & Development Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Blood Plasma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Blood Plasma by Source - Human Plasma Source and Synthetic Plasma Source - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Blood Plasma by Source - Human Plasma Source and Synthetic Plasma Source Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Blood Plasma by Source - Percentage Breakdown of Value Sales for Human Plasma Source and Synthetic Plasma Source for the Years 2014, 2025 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Blood Plasma by Application - Therapeutic Use Application, Diagnostic Use Application and Research & Development Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Blood Plasma by Application - Therapeutic Use Application, Diagnostic Use Application and Research & Development Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Blood Plasma by Application - Percentage Breakdown of Value Sales for Therapeutic Use Application, Diagnostic Use Application and Research & Development Application for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Blood Plasma by Source - Human Plasma Source and Synthetic Plasma Source - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Blood Plasma by Source - Human Plasma Source and Synthetic Plasma Source Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Blood Plasma by Source - Percentage Breakdown of Value Sales for Human Plasma Source and Synthetic Plasma Source for the Years 2014, 2025 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Blood Plasma by Application - Therapeutic Use Application, Diagnostic Use Application and Research & Development Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Blood Plasma by Application - Therapeutic Use Application, Diagnostic Use Application and Research & Development Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Blood Plasma by Application - Percentage Breakdown of Value Sales for Therapeutic Use Application, Diagnostic Use Application and Research & Development Application for the Years 2014, 2025 & 2030
  • JAPAN
    • Blood Plasma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Blood Plasma by Source - Human Plasma Source and Synthetic Plasma Source - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Blood Plasma by Source - Human Plasma Source and Synthetic Plasma Source Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Blood Plasma by Source - Percentage Breakdown of Value Sales for Human Plasma Source and Synthetic Plasma Source for the Years 2014, 2025 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Blood Plasma by Application - Therapeutic Use Application, Diagnostic Use Application and Research & Development Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Blood Plasma by Application - Therapeutic Use Application, Diagnostic Use Application and Research & Development Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Blood Plasma by Application - Percentage Breakdown of Value Sales for Therapeutic Use Application, Diagnostic Use Application and Research & Development Application for the Years 2014, 2025 & 2030
  • CHINA
    • Blood Plasma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Blood Plasma by Source - Human Plasma Source and Synthetic Plasma Source - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Blood Plasma by Source - Human Plasma Source and Synthetic Plasma Source Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: China 16-Year Perspective for Blood Plasma by Source - Percentage Breakdown of Value Sales for Human Plasma Source and Synthetic Plasma Source for the Years 2014, 2025 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Blood Plasma by Application - Therapeutic Use Application, Diagnostic Use Application and Research & Development Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Blood Plasma by Application - Therapeutic Use Application, Diagnostic Use Application and Research & Development Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: China 16-Year Perspective for Blood Plasma by Application - Percentage Breakdown of Value Sales for Therapeutic Use Application, Diagnostic Use Application and Research & Development Application for the Years 2014, 2025 & 2030
  • EUROPE
    • Blood Plasma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Blood Plasma by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Blood Plasma by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Blood Plasma by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Blood Plasma by Source - Human Plasma Source and Synthetic Plasma Source - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Blood Plasma by Source - Human Plasma Source and Synthetic Plasma Source Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Blood Plasma by Source - Percentage Breakdown of Value Sales for Human Plasma Source and Synthetic Plasma Source for the Years 2014, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Blood Plasma by Application - Therapeutic Use Application, Diagnostic Use Application and Research & Development Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Blood Plasma by Application - Therapeutic Use Application, Diagnostic Use Application and Research & Development Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Blood Plasma by Application - Percentage Breakdown of Value Sales for Therapeutic Use Application, Diagnostic Use Application and Research & Development Application for the Years 2014, 2025 & 2030
  • FRANCE
    • Blood Plasma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Blood Plasma by Source - Human Plasma Source and Synthetic Plasma Source - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Blood Plasma by Source - Human Plasma Source and Synthetic Plasma Source Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: France 16-Year Perspective for Blood Plasma by Source - Percentage Breakdown of Value Sales for Human Plasma Source and Synthetic Plasma Source for the Years 2014, 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Blood Plasma by Application - Therapeutic Use Application, Diagnostic Use Application and Research & Development Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Blood Plasma by Application - Therapeutic Use Application, Diagnostic Use Application and Research & Development Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: France 16-Year Perspective for Blood Plasma by Application - Percentage Breakdown of Value Sales for Therapeutic Use Application, Diagnostic Use Application and Research & Development Application for the Years 2014, 2025 & 2030
  • GERMANY
    • Blood Plasma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Blood Plasma by Source - Human Plasma Source and Synthetic Plasma Source - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Blood Plasma by Source - Human Plasma Source and Synthetic Plasma Source Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Blood Plasma by Source - Percentage Breakdown of Value Sales for Human Plasma Source and Synthetic Plasma Source for the Years 2014, 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Blood Plasma by Application - Therapeutic Use Application, Diagnostic Use Application and Research & Development Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Blood Plasma by Application - Therapeutic Use Application, Diagnostic Use Application and Research & Development Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Blood Plasma by Application - Percentage Breakdown of Value Sales for Therapeutic Use Application, Diagnostic Use Application and Research & Development Application for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Blood Plasma by Source - Human Plasma Source and Synthetic Plasma Source - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Blood Plasma by Source - Human Plasma Source and Synthetic Plasma Source Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Blood Plasma by Source - Percentage Breakdown of Value Sales for Human Plasma Source and Synthetic Plasma Source for the Years 2014, 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Blood Plasma by Application - Therapeutic Use Application, Diagnostic Use Application and Research & Development Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Blood Plasma by Application - Therapeutic Use Application, Diagnostic Use Application and Research & Development Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Blood Plasma by Application - Percentage Breakdown of Value Sales for Therapeutic Use Application, Diagnostic Use Application and Research & Development Application for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Blood Plasma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Blood Plasma by Source - Human Plasma Source and Synthetic Plasma Source - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Blood Plasma by Source - Human Plasma Source and Synthetic Plasma Source Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Blood Plasma by Source - Percentage Breakdown of Value Sales for Human Plasma Source and Synthetic Plasma Source for the Years 2014, 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Blood Plasma by Application - Therapeutic Use Application, Diagnostic Use Application and Research & Development Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Blood Plasma by Application - Therapeutic Use Application, Diagnostic Use Application and Research & Development Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Blood Plasma by Application - Percentage Breakdown of Value Sales for Therapeutic Use Application, Diagnostic Use Application and Research & Development Application for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Blood Plasma by Source - Human Plasma Source and Synthetic Plasma Source - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Blood Plasma by Source - Human Plasma Source and Synthetic Plasma Source Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Spain 16-Year Perspective for Blood Plasma by Source - Percentage Breakdown of Value Sales for Human Plasma Source and Synthetic Plasma Source for the Years 2014, 2025 & 2030
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Blood Plasma by Application - Therapeutic Use Application, Diagnostic Use Application and Research & Development Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Blood Plasma by Application - Therapeutic Use Application, Diagnostic Use Application and Research & Development Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Blood Plasma by Application - Percentage Breakdown of Value Sales for Therapeutic Use Application, Diagnostic Use Application and Research & Development Application for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Blood Plasma by Source - Human Plasma Source and Synthetic Plasma Source - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Blood Plasma by Source - Human Plasma Source and Synthetic Plasma Source Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Russia 16-Year Perspective for Blood Plasma by Source - Percentage Breakdown of Value Sales for Human Plasma Source and Synthetic Plasma Source for the Years 2014, 2025 & 2030
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Blood Plasma by Application - Therapeutic Use Application, Diagnostic Use Application and Research & Development Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Blood Plasma by Application - Therapeutic Use Application, Diagnostic Use Application and Research & Development Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Blood Plasma by Application - Percentage Breakdown of Value Sales for Therapeutic Use Application, Diagnostic Use Application and Research & Development Application for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Blood Plasma by Source - Human Plasma Source and Synthetic Plasma Source - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Blood Plasma by Source - Human Plasma Source and Synthetic Plasma Source Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for Blood Plasma by Source - Percentage Breakdown of Value Sales for Human Plasma Source and Synthetic Plasma Source for the Years 2014, 2025 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Blood Plasma by Application - Therapeutic Use Application, Diagnostic Use Application and Research & Development Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Blood Plasma by Application - Therapeutic Use Application, Diagnostic Use Application and Research & Development Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Blood Plasma by Application - Percentage Breakdown of Value Sales for Therapeutic Use Application, Diagnostic Use Application and Research & Development Application for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Blood Plasma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Blood Plasma by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Blood Plasma by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for Blood Plasma by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Blood Plasma by Source - Human Plasma Source and Synthetic Plasma Source - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Blood Plasma by Source - Human Plasma Source and Synthetic Plasma Source Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Blood Plasma by Source - Percentage Breakdown of Value Sales for Human Plasma Source and Synthetic Plasma Source for the Years 2014, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Blood Plasma by Application - Therapeutic Use Application, Diagnostic Use Application and Research & Development Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Blood Plasma by Application - Therapeutic Use Application, Diagnostic Use Application and Research & Development Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Blood Plasma by Application - Percentage Breakdown of Value Sales for Therapeutic Use Application, Diagnostic Use Application and Research & Development Application for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Blood Plasma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Blood Plasma by Source - Human Plasma Source and Synthetic Plasma Source - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Blood Plasma by Source - Human Plasma Source and Synthetic Plasma Source Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Australia 16-Year Perspective for Blood Plasma by Source - Percentage Breakdown of Value Sales for Human Plasma Source and Synthetic Plasma Source for the Years 2014, 2025 & 2030
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Blood Plasma by Application - Therapeutic Use Application, Diagnostic Use Application and Research & Development Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Blood Plasma by Application - Therapeutic Use Application, Diagnostic Use Application and Research & Development Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Blood Plasma by Application - Percentage Breakdown of Value Sales for Therapeutic Use Application, Diagnostic Use Application and Research & Development Application for the Years 2014, 2025 & 2030
  • INDIA
    • Blood Plasma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 110: India Recent Past, Current & Future Analysis for Blood Plasma by Source - Human Plasma Source and Synthetic Plasma Source - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Blood Plasma by Source - Human Plasma Source and Synthetic Plasma Source Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: India 16-Year Perspective for Blood Plasma by Source - Percentage Breakdown of Value Sales for Human Plasma Source and Synthetic Plasma Source for the Years 2014, 2025 & 2030
    • TABLE 113: India Recent Past, Current & Future Analysis for Blood Plasma by Application - Therapeutic Use Application, Diagnostic Use Application and Research & Development Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Blood Plasma by Application - Therapeutic Use Application, Diagnostic Use Application and Research & Development Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: India 16-Year Perspective for Blood Plasma by Application - Percentage Breakdown of Value Sales for Therapeutic Use Application, Diagnostic Use Application and Research & Development Application for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Blood Plasma by Source - Human Plasma Source and Synthetic Plasma Source - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Blood Plasma by Source - Human Plasma Source and Synthetic Plasma Source Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: South Korea 16-Year Perspective for Blood Plasma by Source - Percentage Breakdown of Value Sales for Human Plasma Source and Synthetic Plasma Source for the Years 2014, 2025 & 2030
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Blood Plasma by Application - Therapeutic Use Application, Diagnostic Use Application and Research & Development Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Blood Plasma by Application - Therapeutic Use Application, Diagnostic Use Application and Research & Development Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Blood Plasma by Application - Percentage Breakdown of Value Sales for Therapeutic Use Application, Diagnostic Use Application and Research & Development Application for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Blood Plasma by Source - Human Plasma Source and Synthetic Plasma Source - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Blood Plasma by Source - Human Plasma Source and Synthetic Plasma Source Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 16-Year Perspective for Blood Plasma by Source - Percentage Breakdown of Value Sales for Human Plasma Source and Synthetic Plasma Source for the Years 2014, 2025 & 2030
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Blood Plasma by Application - Therapeutic Use Application, Diagnostic Use Application and Research & Development Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Blood Plasma by Application - Therapeutic Use Application, Diagnostic Use Application and Research & Development Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Blood Plasma by Application - Percentage Breakdown of Value Sales for Therapeutic Use Application, Diagnostic Use Application and Research & Development Application for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Blood Plasma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Blood Plasma by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Blood Plasma by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Latin America 16-Year Perspective for Blood Plasma by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Blood Plasma by Source - Human Plasma Source and Synthetic Plasma Source - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Blood Plasma by Source - Human Plasma Source and Synthetic Plasma Source Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Blood Plasma by Source - Percentage Breakdown of Value Sales for Human Plasma Source and Synthetic Plasma Source for the Years 2014, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Blood Plasma by Application - Therapeutic Use Application, Diagnostic Use Application and Research & Development Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Blood Plasma by Application - Therapeutic Use Application, Diagnostic Use Application and Research & Development Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Blood Plasma by Application - Percentage Breakdown of Value Sales for Therapeutic Use Application, Diagnostic Use Application and Research & Development Application for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Blood Plasma by Source - Human Plasma Source and Synthetic Plasma Source - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Blood Plasma by Source - Human Plasma Source and Synthetic Plasma Source Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Argentina 16-Year Perspective for Blood Plasma by Source - Percentage Breakdown of Value Sales for Human Plasma Source and Synthetic Plasma Source for the Years 2014, 2025 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Blood Plasma by Application - Therapeutic Use Application, Diagnostic Use Application and Research & Development Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Blood Plasma by Application - Therapeutic Use Application, Diagnostic Use Application and Research & Development Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Blood Plasma by Application - Percentage Breakdown of Value Sales for Therapeutic Use Application, Diagnostic Use Application and Research & Development Application for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Blood Plasma by Source - Human Plasma Source and Synthetic Plasma Source - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Blood Plasma by Source - Human Plasma Source and Synthetic Plasma Source Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Brazil 16-Year Perspective for Blood Plasma by Source - Percentage Breakdown of Value Sales for Human Plasma Source and Synthetic Plasma Source for the Years 2014, 2025 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Blood Plasma by Application - Therapeutic Use Application, Diagnostic Use Application and Research & Development Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Blood Plasma by Application - Therapeutic Use Application, Diagnostic Use Application and Research & Development Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Blood Plasma by Application - Percentage Breakdown of Value Sales for Therapeutic Use Application, Diagnostic Use Application and Research & Development Application for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Blood Plasma by Source - Human Plasma Source and Synthetic Plasma Source - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Blood Plasma by Source - Human Plasma Source and Synthetic Plasma Source Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Mexico 16-Year Perspective for Blood Plasma by Source - Percentage Breakdown of Value Sales for Human Plasma Source and Synthetic Plasma Source for the Years 2014, 2025 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Blood Plasma by Application - Therapeutic Use Application, Diagnostic Use Application and Research & Development Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Blood Plasma by Application - Therapeutic Use Application, Diagnostic Use Application and Research & Development Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Blood Plasma by Application - Percentage Breakdown of Value Sales for Therapeutic Use Application, Diagnostic Use Application and Research & Development Application for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Blood Plasma by Source - Human Plasma Source and Synthetic Plasma Source - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Blood Plasma by Source - Human Plasma Source and Synthetic Plasma Source Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 16-Year Perspective for Blood Plasma by Source - Percentage Breakdown of Value Sales for Human Plasma Source and Synthetic Plasma Source for the Years 2014, 2025 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Blood Plasma by Application - Therapeutic Use Application, Diagnostic Use Application and Research & Development Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Blood Plasma by Application - Therapeutic Use Application, Diagnostic Use Application and Research & Development Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Blood Plasma by Application - Percentage Breakdown of Value Sales for Therapeutic Use Application, Diagnostic Use Application and Research & Development Application for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Blood Plasma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Blood Plasma by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Blood Plasma by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Middle East 16-Year Perspective for Blood Plasma by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Blood Plasma by Source - Human Plasma Source and Synthetic Plasma Source - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Blood Plasma by Source - Human Plasma Source and Synthetic Plasma Source Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Blood Plasma by Source - Percentage Breakdown of Value Sales for Human Plasma Source and Synthetic Plasma Source for the Years 2014, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Blood Plasma by Application - Therapeutic Use Application, Diagnostic Use Application and Research & Development Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Blood Plasma by Application - Therapeutic Use Application, Diagnostic Use Application and Research & Development Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Blood Plasma by Application - Percentage Breakdown of Value Sales for Therapeutic Use Application, Diagnostic Use Application and Research & Development Application for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Blood Plasma by Source - Human Plasma Source and Synthetic Plasma Source - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Blood Plasma by Source - Human Plasma Source and Synthetic Plasma Source Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Iran 16-Year Perspective for Blood Plasma by Source - Percentage Breakdown of Value Sales for Human Plasma Source and Synthetic Plasma Source for the Years 2014, 2025 & 2030
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Blood Plasma by Application - Therapeutic Use Application, Diagnostic Use Application and Research & Development Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Blood Plasma by Application - Therapeutic Use Application, Diagnostic Use Application and Research & Development Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Blood Plasma by Application - Percentage Breakdown of Value Sales for Therapeutic Use Application, Diagnostic Use Application and Research & Development Application for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Blood Plasma by Source - Human Plasma Source and Synthetic Plasma Source - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Blood Plasma by Source - Human Plasma Source and Synthetic Plasma Source Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Israel 16-Year Perspective for Blood Plasma by Source - Percentage Breakdown of Value Sales for Human Plasma Source and Synthetic Plasma Source for the Years 2014, 2025 & 2030
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Blood Plasma by Application - Therapeutic Use Application, Diagnostic Use Application and Research & Development Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Blood Plasma by Application - Therapeutic Use Application, Diagnostic Use Application and Research & Development Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Blood Plasma by Application - Percentage Breakdown of Value Sales for Therapeutic Use Application, Diagnostic Use Application and Research & Development Application for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Blood Plasma by Source - Human Plasma Source and Synthetic Plasma Source - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Blood Plasma by Source - Human Plasma Source and Synthetic Plasma Source Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 16-Year Perspective for Blood Plasma by Source - Percentage Breakdown of Value Sales for Human Plasma Source and Synthetic Plasma Source for the Years 2014, 2025 & 2030
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Blood Plasma by Application - Therapeutic Use Application, Diagnostic Use Application and Research & Development Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Blood Plasma by Application - Therapeutic Use Application, Diagnostic Use Application and Research & Development Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Blood Plasma by Application - Percentage Breakdown of Value Sales for Therapeutic Use Application, Diagnostic Use Application and Research & Development Application for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Blood Plasma by Source - Human Plasma Source and Synthetic Plasma Source - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Blood Plasma by Source - Human Plasma Source and Synthetic Plasma Source Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: UAE 16-Year Perspective for Blood Plasma by Source - Percentage Breakdown of Value Sales for Human Plasma Source and Synthetic Plasma Source for the Years 2014, 2025 & 2030
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Blood Plasma by Application - Therapeutic Use Application, Diagnostic Use Application and Research & Development Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Blood Plasma by Application - Therapeutic Use Application, Diagnostic Use Application and Research & Development Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Blood Plasma by Application - Percentage Breakdown of Value Sales for Therapeutic Use Application, Diagnostic Use Application and Research & Development Application for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Blood Plasma by Source - Human Plasma Source and Synthetic Plasma Source - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Blood Plasma by Source - Human Plasma Source and Synthetic Plasma Source Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 16-Year Perspective for Blood Plasma by Source - Percentage Breakdown of Value Sales for Human Plasma Source and Synthetic Plasma Source for the Years 2014, 2025 & 2030
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Blood Plasma by Application - Therapeutic Use Application, Diagnostic Use Application and Research & Development Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Blood Plasma by Application - Therapeutic Use Application, Diagnostic Use Application and Research & Development Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Blood Plasma by Application - Percentage Breakdown of Value Sales for Therapeutic Use Application, Diagnostic Use Application and Research & Development Application for the Years 2014, 2025 & 2030
  • AFRICA
    • Blood Plasma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Blood Plasma by Source - Human Plasma Source and Synthetic Plasma Source - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Blood Plasma by Source - Human Plasma Source and Synthetic Plasma Source Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Africa 16-Year Perspective for Blood Plasma by Source - Percentage Breakdown of Value Sales for Human Plasma Source and Synthetic Plasma Source for the Years 2014, 2025 & 2030
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Blood Plasma by Application - Therapeutic Use Application, Diagnostic Use Application and Research & Development Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Blood Plasma by Application - Therapeutic Use Application, Diagnostic Use Application and Research & Development Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Blood Plasma by Application - Percentage Breakdown of Value Sales for Therapeutic Use Application, Diagnostic Use Application and Research & Development Application for the Years 2014, 2025 & 2030

IV. COMPETITION